Lasers in Surgery and Medicine · 2012 · 193 citations · 29 references
MedicineNeurosurgerySurgeryNeuro-oncologyOncologic SurgerySurgical OncologyBrain Metastasis ManagementBrain TumorsGlioblastomaLaser SurgeryPhotothermal TherapyRecurrent Brain TumorsApplicator PlacementGlioblastoma SurgeryGlioma SurgeryLasersNeurological DeteriorationStereotactic ResectionTumor Laser Ablation
BACKGROUND AND OBJECTIVE: Laser-induced thermal therapy (LITT), coupled with magnetic resonance thermal imaging (MRTI) guidance, provides a minimally invasive and safe approach to treat brain tumors, especially metastases. We report here our experience using this treatment for recurrent glioblastomas. MATERIALS AND METHODS: Four patients, from 40 to 58 years old, were diagnosed with glioblastoma. After total resection, chemotherapy and radiation therapy, recurrence occurred. As each was ineligible for a second surgery, LITT was proposed as salvage therapy. Under stereotactic guidance, a fiberoptic applicator was inserted within the tumor LITT was performed under continuous MRTI. Real-time feedback control based on MRTI was employed to assess the quality of local tissue destruction and to prevent unwanted damage to nearby structures. RESULTS: The procedure was well tolerated with no peroperative neurological deterioration. In the short-term follow-up, one transient supplementary motor area syndrome, one epileptic seizure, and one cerebrospinal fluid leakage occurred. All were successfully managed. Post-procedure MRI showed no complication, satisfying treatment volume, and a decrease in size of the treated tumor. For all patients, recurrence was observed with a mean/median progression free survival of 37/30 days. Mean/median overall survival after LITT was 10.5/10 months. CONCLUSION: Focal tumor control was performed safely using minimally invasive LITT with real-time MRTI control. LITT could be considered as salvage therapy for high-grade recurrent gliomas if a 1-day treatment is considered useful for a few weeks gain in survival. Larger experience will be required to define indications for such infiltrative disease and accurately determine a potentially significant survival gain in good neurological condition associated with this 1-day procedure.
29
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations
Survival and Functional Status after Resection of Recurrent Glioblastoma Multiforme
Fred G. Barker, Susan M. Chang, Philip H. Gutin et al. · Neurosurgery · 1998 · 332 citations
Medicine, Neurosurgery, Oncology +14